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ABSTRACT
Background: Heparin is a potential anti-inflammatory drug for allergic airway inflammation. To elucidate the
effects of heparin on allergic inflammation, we examined the in vivo effects of heparin on antigen-induced mu-
cus hypersecretion and infiltration of eosinophils and neutrophils in the nasal epithelium of sensitized rats.
Methods: We induced hypertrophic and metaplastic changes of goblet cells in the nasal epithelium of ovalbu-
min (OVA)-sensitized rats by intranasal challenge with OVA. The effects of intranasal instillation with low mo-
lecular weight heparin (LMWH; 1-1000 IU0.1 ml) on mucus production and eosinophilneutrophil infiltration
were examined.
Results: Intranasal instillation with low-dose LMWH (1-10 IU0.1 ml) at 30 minutes before OVA instillation
stimulated OVA-induced mucus production in the nasal epithelium of sensitized rats, whereas treatment with
100 IU0.1 ml LMWH showed no effect. Intranasal instillation with high-dose LMWH (1000 IU0.1 ml) signifi-
cantly inhibited OVA-induced mucus production. Intranasal instillation with LMWH (1-1000 IU0.1 ml) dose-
dependently inhibited eosinophil and neutrophil infiltration into the rat nasal mucosa.
Conclusions: These results indicate that heparin inhibits mucus hypersecretion and infiltration of eosinophils
and neutrophils in allergic inflammation, though the inhibitory effect against mucus production is obtained in
high-dose heparin. Intranasal instillation with high-dose heparin may provide a new therapeutic strategy for the
treatment of nasal allergic inflammation.
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INTRODUCTION
Hypersecretion of mucus is an important characteris-
tic of allergic inflammation such as allergic rhinitis
and bronchial asthma. Ovalbumin (OVA)-sensitized
animals have been used to study the pathophysi-
ologic changes in allergic inflammation in airways, in-
cluding plasma extravasation, eosinophil infiltration,
and mucus hypersecretion.1 A variety of allergic me-
diators and inflammatory cells are capable of stimulat-
ing mucus hypersecretion. We previously reported
that thrombin, an enzyme formed during activation of
the coagulation system, plays an important role in air-
way inflammation by stimulating mucus hypersecre-
tion and production of cytokines and growth factors
from epithelial cells.2 We also demonstrated the pres-
ence of thrombin in nasal secretion from patients
with allergic rhinitis, and activation of coagulation
system is implicated in the pathogenesis of airway al-
lergic inflammation.3
Heparin has been used as one of the most impor-
tant anticoagulant drugs in clinical practice, and it
also possesses the anti-inflammatory activities by
binding nonspecifically to many proteins involved in
the inflammatory process, including cytokines,
growth factors, adhesion molecules and tissue-
destructive enzymes.4,5 In the previous study, we re-
vealed that heparin inhibited TNF-α-induced produc-
tion of mucin and IL-8 in cultured human airway epi-
thelial cells, and that intranasal instillation with hepa-
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Fig.　1　Time line for intraperitoneal sensitization and intranasal challenge with OVA, and in-
tranasal instillation with LMWH at 30 min before OVA challenge.
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rin significantly inhibited lipopolysaccharides (LPS)-
induced mucus hypersecretion and neutrophil infil-
tration in rat nasal epithelium.6 Recently, potential
anti-inflammatory effects of heparin in allergic inflam-
mation have been examined by animal studies and
several clinical trials on patients with allergic rhinitis
and bronchial asthma.7-11 However, the mechanism
responsible for the anti-inflammatory effects of hepa-
rin is not well understood, and the effect of heparin
on allergic inflammation is still unclear.
In the present study, to elucidate the effects of
heparin on mucus hypersecretion in allergic airway
inflammation, we induced hypertrophic and mataplas-
tic changes of goblet cells in the nasal epithelium of
OVA-sensitized rats by intranasal challenge with
OVA. The in vivo effects of intranasal instillation with
heparin on mucus hypersecretion and on eosinophil
and neutrophil infiltration were then examined.
METHODS
SENSITIZATION AND INTRANASAL CHAL-
LENGEWITH OVA
The experimental protocol was approved by the Com-
mittee for Animal Care and Ethics of Shiga University
of Medical Science and it was carried out following
the guidelines of the National Institute of Health. Sen-
sitization and challenge of rats were performed as
previously described.1 Specific pathogen-free male
Fisher-344 rats (6 rats in each group) 6 weeks of age
were used in this study. Rats were sensitized with an
intraperitoneal injection of 1 ml of saline solution con-
taining 200 μg of OVA (grade V; Sigma-Aldrich Corp.,
St Louis, Missouri, USA) and 5 mg of aluminum hy-
droxide [Al(OH)3] on days 1, 2, 3, and 10. On day 21,
rats were anesthetized with ether, and 0.1 ml of saline
solution containing 10 mg of OVA was instilled into
both airways of the nasal cavity once a day for 3 days.
Sham-challenged rats received 0.1 ml saline solution
in the same manner (Fig. 1). LMWH (enoxaparin;
Clexane, Sanofi-Aventis Pharmaceutical Co., Paris,
France); 1-1000 IU in 0.1 ml saline, were intranasally
instilled at 30 minutes before the intranasal challenge
with OVA for 3 consecutive days.
TISSUE PREPARATION
The rats were painlessly killed with an intraperitoneal
overdose of sodium pentobarbital at 24 hours after
the last intranasal challenge with OVA. The head of
each rat was removed and fixed in 10% neutral buff-
ered formalin for 3 days, then decalcified in 5%
trichloroacetic acid for 10 days. The nasal cavity was
transversely sectioned at the level of incisive papilla
of the hard palate.12 The tissue block was embedded
in paraffin.
MORPHOMETRY
Tissue sections 4 μm thick were stained with Alcian
blue (pH 2.6), periodic acid-Schiff (AB-PAS) and he-
matoxylin. The percent area of AB-PAS stained muco-
substance in the epithelial surface was determined by
an image analyzer in nasal epithelium over 2 mm (1
mm each side of the nasal septum) of the basal lam-
ina at the center of the septal cartilage (magnification
×400).12 The infiltrating eosinophils and neutrophils
in nasal mucosa were examined with Hematoxylin-
eosin staining. The numbers of eosinophils and neu-
trophils in the nasal septal mucosa were counted over
both sides of the septal cartilage by use of an oil im-
mersion objective lens (magnification ×1,000). All
measurements were done by one blinded observer.
STATISTICS
All data are expressed as mean ± SD. The difference
between variables was analyzed by the Mann-
Whitney U test. Probability (p) values of less than
0.05 were considered statistically significant.
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Fig.　2　Effects of LMWH on goblet cell metaplasia and mucus production in the nasal epithelium 
of sensitized rats. (A) Saline-treated saline-challenged control. (B) LMWH (100 IU/0.1 ml)-treated 
saline-challenged rats. (C) Saline-treated OVA-challenged rats. (D) LMWH (1 IU/0.1 ml)-treated 
OVA-challenged rats. (E) LMWH (10 IU/0.1 ml)-treated OVA-challenged rats. (F) LMWH (100 
IU/0.1 ml)-treated OVA-challenged rats. Intranasal instillation with OVA induced goblet cell meta-
plasia and mucus production. Intranasal instillation with LMWH (1-10 IU/0.1 ml) stimulated these 
changes, whereas LMWH (100 IU/0.1ml) showed no effects. Scale bars represent 30 μm.
Fig.　3　Effects of LMWH on antigen-induced mucus produc-
tion in the nasal epithelium of sensitized rats (n = 6). Intrana-
sal instillation with OVA signifi cantly induced mucus produc-
tion. Intranasal instillation with low-dose LMWH (1-10 IU/0.1 
ml) stimulated antigen-induced mucus production whereas 
LMWH (100 IU/0.1 ml) showed no effects. **P < .01.
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RESULTS
Intranasal instillation with OVA (10 mg0.1 ml) for 3
consecutive days significantly induced hypertrophic
and metaplastic changes of goblet cells in the nasal
septal epithelium of OVA-sensitized rats. Only a few
goblet cells were observed in control groups; saline-
instilled, or LMWH (100 IU0.1 ml)-instilled rats. The
effects of intranasal instillation with LMWH (1-100
IU0.1 ml) at 30 minutes before OVA instillation on
OVA-induced mucus production are shown in Figure
2. Intranasal instillation with low-dose LMWH (1-10
IU0.1 ml) stimulated OVA-induced hyperplastic
changes of goblet cells. Quantitative changes in the
percent area of mucosubstance in this epithelium are
described in Figure 3. Low-dose LMWH (1-10 IU0.1
ml) significantly stimulated OVA-induced mucus pro-
duction, whereas treatment with LMWH (100 IU0.1
ml) showed no effect. Intranasal instillation with OVA
also induced eosinophil and neutrophil infiltration in
the nasal septal mucosa of sensitized rats at 24 hours
after the last OVA challenge. Intranasal instillation
with LMWH (1-100 IU0.1 ml) dose-dependently in-
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Fig.　4　Effects of LMWH (1-100 IU/0.1 ml) on antigen-in-
duced eosinophil infi ltration in the nasal mucosa of sensitized 
rats (n = 6). Intranasal instillation with LMWH (1-100 IU/0.1 
ml) dose-dependently inhibited antigen-induced eosinophil in-
fi ltration. *P < .05, **P < .01.
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Fig.　5　Effects of LMWH (1-100 IU/0.1 ml) on antigen-in-
duced neutrophil infi ltration in the nasal mucosa of sensitized 
rats (n = 6). Intranasal instillation with LMWH dose-depend-
ently inhibited antigen-induced neutrophil infi ltration.
*P < .05, **P < .01.
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Fig.　6　Effects of high-dose LMWH (1000 IU/0.1 ml) on goblet cell meta-
plasia and mucus production in the nasal epithelium of sensitized rats. A) 
Saline-treated OVA-challenged rats. B) LMWH (1000 IU/0.1 ml)-treated 
OVA-challenged rats. Intranasal instillation with high-dose LMWH inhibited 
antigen-induced goblet cell metaplasia and mucus production. Scale bars 
represent 30 μm. C) Effects of high-dose LMWH (1000 IU/0.1 ml) on mucus 
production in the nasal epithelium of sensitized rats (n = 6). Quantitative 
analysis revealed that intranasal instillation with high-dose LMWH signifi -
cantly inhibited antigen-induced mucus production. **P < .01.
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hibited OVA-induced eosinophil and neutrophil infil-
tration (Fig. 4, 5).
We next examined the effects of high-dose LMWH
(1000 IU0.1 ml) on OVA-induced mucus production.
Intranasal instillation with high-dose LMWH (1000
IU0.1 ml) significantly inhibited OVA-induced chan-
ges of goblet cells (Fig. 6). Quantitative examination
revealed the significant inhibition with high-dose
LMWH (1000 IU0.1 ml) on OVA-induced mucus
production. OVA-induced eosinophil and neutrophil
infiltration in nasal septal mucosa was also signifi-
cantly inhibited by intranasal instillation with high-
dose LMWH (1000 IU0.1 ml) (Fig. 7).
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Fig.　7　Effects of high-dose LMWH (1000 IU/0.1 ml) on an-
tigen-induced infi ltrations of eosinophils (A) and neutrophils 
(B) in the nasal mucosa of sensitized rats (n = 6). Intranasal 
instillation with high-dose LMWH signifi cantly inhibited anti-
gen-induced infi ltrations of eosinophils and neutrophils. 
**P < .01.
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DISCUSSION
In the present study, intranasal instillation with OVA
induced hypertrophic and metaplastic changes of
goblet cells and mucosal infiltration of eosinophils
and neutrophils in the nasal epithelium of OVA-
sensitized rats. Intranasal instillation with high-dose
LMWH (1000 IU0.1 ml) significantly inhibited OVA-
induced mucus production, whereas treatment with
low-dose LMWH (1-10 IU0.1 ml) stimulated it.
Antigen-induced infiltrations of eosinophils and neu-
trophils were dose-dependently inhibited by LMWH
(1-1000 IU0.1 ml).
Heparin has been used for a long time in clinical
practice as an anticoagulant drug. It has been known
that heparin also had anti-inflammatory functions,
and animal models have been used to study the regu-
latory effects of heparin on allergic inflammation.5 In-
haled heparin reduced antigen-induced airway hyper-
reactivity in experimental model of asthma in rat8 and
sheep,7,13,14 and it attenuated the nasal airway pres-
sure and cellular infiltration in nasal lavage fluid in a
gunea pig model of nasal allergy.15 Several clinical
studies revealed the anti-inflammatory effects of
heparin in patients with bronchial asthma9,10,16 and al-
lergic rhinitis.11,17 Inhaled heparin inhibited the bron-
choconstrictive response in patients with exercise-
induced asthma.9 Heparin attenuated asthmatic re-
sponses in two patients with corticosteroid-resistant
asthma.10 Inhaled intranasal heparin reduced antigen-
induced nasal symptoms in patients with allergic
rhinitis.11 However, little is known about the regula-
tory effects of heparin on antigen-induced mucus pro-
duction, and this is the first report showing the effect
of heparin on goblet cell metaplasia and mucus hy-
persecretion in nasal epithelium of allergic inflamma-
tion.
The mechanism by which high-dose LMWH inhib-
its antigen-induced mucus production is not well un-
derstood. Airway inflammation is associated with in-
creased vascular permeability and leakage of plasma
coagulation factors, leading to activation of the coagu-
lation system in the extravascular space.18 We previ-
ously reported that significant concentrations of
thrombin and thrombin-antithrombin complex were
found in nasal secretion from patients with allergic
rhinitis.3 Thrombin and its agonistic receptor peptide
stimulated the mucus secretion from cultured nasal
epithelial cells in vitro, and intranasal instillation with
thrombin induced goblet cell metaplasia and mucus
production in rat nasal epithelium in vivo.2 These re-
sults indicate that the activation of coagulation sys-
tem occurs during allergic airway inflammation and
that thrombin plays a crucial role in the regulation of
mucus hypersecretion. We have reported that the an-
ticoagulant, activated protein C, inhibited thrombin-
induced mucus production in rat nasal epithelium.2
The regulatory effects of heparin on mucus hyper-
secretion may be partly caused by its anticoagulatory
function through the inhibition of thrombin.
Heparin shows anti-inflammatory action by binding
to and neutrize a wide variety of inflammatory media-
tors, such as cytokines, chemokines, complement fac-
tors, and extracellular matrix proteins.4,5 We found
that LMWH dose-dependently inhibited antigen-
induced infiltrations of eosinophils and neutrophils in
rat nasal epithelium. These results are consistent
with previous studies showing that heparin inhibited
eosinophil infiltration into the lung in animal model of
asthma.8,19 In our previous study, LMWH attenuated
LPS-induced neutrophil infiltration in rat nasal epithe-
lium, and it also suppressed TNF-α-induced secretion
of IL-8, a neutrophil chemoattractant, from cultured
human airway epithelial cells.6 Leukocyte adhesion
and activation play a central role in the inflammatory
response, and heparin interferes with the adhesion of
leukocyte to the endothelial cells.20,21 The selectins
are responsible for the interaction between leukocyte
and endothelium, and it has been reported that hepa-
rin inhibits these selectin-mediated cell adhe-
sions.22,23 Heparin also inhibits the activation of
eosinophils and neutrophils by binding the leukocyte
adhesion molecule Mac-1.24
The anti-allergic effects of heparin may be related
to the inhibition of mast cell functions. Heparin inhib-
its inositol triphosphate-mediated intracellular cal-
cium release and mast cell degranulation.14 Hista-
mines and lukotrienes are important mast cell media-
tors in the initiation and development of antigen-
induced airway responses. In our previous study, H1-
antagonist inhibited the antigen-induced eosinophil
infiltration in nasal mucosa of sensitized rats, and
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cysLT1 antagonist attenuated the antigen-induced
goblet cell metaplasia and mucus production,1 sug-
gesting that LMWH suppresses the allergic inflam-
mation partially through the inhibition of mast cell de-
granulation.
In the present study, intranasal instillation with
high-dose LMWH (1000 IU0.1 ml) significantly in-
hibited antigen-induced mucus hypersecretion,
whereas the treatment with low-dose LMWH (1-10
IU0.1 ml) stimulated it. We previously reported that
LMWH dose-dependently inhibits LPS-induced mu-
cus production in rat nasal epithelium, and that it sup-
pressed TNF-α-induced secretion of anti-MUC5AC
reactive mucin and mRNA expression of MUC5AC in
cultured human airway epithelial cells.6 The inhibi-
tory effects of high-dose LMWH on mucus hyper-
secretion may be caused by the direct inhibitory ef-
fects on mucus secretion from the epithelial cells and
indirectly through the anti-inflammatory actions
against inflammatory cells and mediators. However,
the mechanism of the adverse response against low-
dose LMWH on antigen-induced mucus production is
unclear.
These biphasic responses of LMWH on mucus pro-
duction may be caused by the complex and heteroge-
neous actions of heparin. Nitric oxide (NO) is a po-
tent vasodilator, and heparin has been shown to pro-
mote NO formation in cultured endothelial cells,25
and to preserve myocardial contractility after
ischemia-reperfusion.26 Nasal blood flow is regulated
by the NO released from parasympathetic nitrergic
nerves innervating the nasal mucosal arteries. We
previously reported that the NO contributes an in-
crease in nasal mucosal blood flow induced by sen-
sory and parasymthetic nerve stimulation in rat.27 Re-
cently, NO has been shown to be an important media-
tor that stimulates nasal blood flow, vascular perme-
ability, inflammatory cell infiltration and mucus pro-
duction in allergic inflammation.28,29 There is a possi-
bility that the adverse effect of heparin on mucus pro-
duction may be related to the heparin-induced in-
crease of NO release after parasymthetic nerve stimu-
lation caused by histamine in allergic inflammation.
In the present study, intranasal instillation with
high-dose LMWH (1000 IU0.1 ml) inhibited mucus
hypersecretion in allergic inflammation of rat nasal
epithelium, though low-dose LMWH showed oppo-
site effects. Many researchers have been used high-
dose LMWH or heparin (more than 10000 IU) for the
clinical trials on allergic rhinitis and bronchial
asthma.4,9-11,13,16 Vancheri et al. reported that 15000
IU4 ml of heparin nebulizer was effective for pa-
tients with allergic rhinitis.11 Bendstrup et al. re-
ported that the highest dose of inhaled heparin to use
safely for bronchial asthma was 32000 IU.30 In these
studies, no adverse effect such as bleeding or throm-
bocytopenia has been reported. Our results suggest
that topical application of high-dose LMWH (more
than 10000 IU) may be useful for the clinical treat-
ment of allergic inflammation in upper airways.
In conclusion, we have induced hypertrophic and
metaplastic changes of goblet cells in nasal epithe-
lium of OVA-sensitized rats by intranasal OVA chal-
lenge, and we have demonstrated in this model that
antigen-induced mucus production and mucosal infil-
trations of eosinophils and neutrophils are signifi-
cantly inhibited by intranasal instillation with high-
dose LMWH. Although antigen-induced infiltrations
of eosinophils and neutrophils were dose-depen-
dently inhibited by LMWH, mucus production was
stimulated by low-dose LMWH. These results indi-
cate that LMWH has heterogeneous anti-inflamma-
tory effects in allergic inflammation, and that high-
dose LMWH may provide a new therapeutic strategy
for allergic inflammation. It is hoped that such study
will improve the understanding and treatment of mu-
cus hypersecretion in allergic airway inflammation.
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